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Behavioral/Cognitive

Cholinergic, But Not Dopaminergic or Noradrenergic,
Enhancement Sharpens Visual Spatial Perception in Humans
X Caterina Gratton,1 X Sahar Yousef,2,3 X Esther Aarts,4 Deanna L. Wallace,5 X Mark D’Esposito,6
and X Michael A. Silver2,3,6
1
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3

The neuromodulator acetylcholine modulates spatial integration in visual cortex by altering the balance of inputs that generate neuronal
receptive fields. These cholinergic effects may provide a neurobiological mechanism underlying the modulation of visual representations
by visual spatial attention. However, the consequences of cholinergic enhancement on visuospatial perception in humans are unknown.
We conducted two experiments to test whether enhancing cholinergic signaling selectively alters perceptual measures of visuospatial
interactions in human subjects. In Experiment 1, a double-blind placebo-controlled pharmacology study, we measured how flanking
distractors influenced detection of a small contrast decrement of a peripheral target, as a function of target-flanker distance. We found
that cholinergic enhancement with the cholinesterase inhibitor donepezil improved target detection, and modeling suggested that this
was mainly due to a narrowing of the extent of facilitatory perceptual spatial interactions. In Experiment 2, we tested whether these effects
were selective to the cholinergic system or would also be observed following enhancements of related neuromodulators dopamine or
norepinephrine. Unlike cholinergic enhancement, dopamine (bromocriptine) and norepinephrine (guanfacine) manipulations did not
improve performance or systematically alter the spatial profile of perceptual interactions between targets and distractors. These findings
reveal mechanisms by which cholinergic signaling influences visual spatial interactions in perception and improves processing of a visual
target among distractors, effects that are notably similar to those of spatial selective attention.
Key words: acetylcholine; attention; dopamine; norepinephrine; pharmacology; visuospatial perception

Significance Statement
Acetylcholine influences how visual cortical neurons integrate signals across space, perhaps providing a neurobiological mechanism for the effects of visual selective attention. However, the influence of cholinergic enhancement on visuospatial perception
remains unknown. Here we demonstrate that cholinergic enhancement improves detection of a target flanked by distractors,
consistent with sharpened visuospatial perceptual representations. Furthermore, whereas most pharmacological studies focus on
a single neurotransmitter, many neuromodulators can have related effects on cognition and perception. Thus, we also demonstrate that enhancing noradrenergic and dopaminergic systems does not systematically improve visuospatial perception or alter
its tuning. Our results link visuospatial tuning effects of acetylcholine at the neuronal and perceptual levels and provide insights
into the connection between cholinergic signaling and visual attention.

Neuromodulators such as acetylcholine (ACh), dopamine (DA),
and norepinephrine (NE) play important roles in spatial atten-

tion and its influence on perception and sensory processing (for
reviews, see Sarter et al., 2005; Bentley et al., 2011; Hasselmo and
Sarter, 2011; Noudoost and Moore, 2011b; Thiele, 2013). In par-

Received July 26, 2016; revised March 11, 2017; accepted March 16, 2017.
Author contributions: C.G., M.D., and M.A.S. designed research; C.G., S.Y., and E.A. performed research; C.G. and
M.A.S. analyzed data; C.G., E.A., D.L.W., M.D., and M.A.S. wrote the paper.
This work was supported by National Institute on Drug Abuse R01 DA34684 to M.D., National Eye Institute R01
025278 to M.A.S., National Science Foundation Graduate Research and National Defense Science and Engineering
Graduate Fellowships to C.G, and National Eye Institute Core Grant EY003176. We thank Anthony LaBarbera, Char-

lotte Gissel, and Katie Cheng for their help with data collection, David Bressler and Ariel Rokem for analysis advice,
and Lauri Nurminen for helpful discussions about interpretation of our results.
The authors declare no competing financial interests.
Correspondence should be addressed to Dr. Caterina Gratton, 4525 Scott Avenue, Room 2220, Campus Box 8111,
Washington University, St. Louis, MO 63110. E-mail: cgratton@wustl.edu.
DOI:10.1523/JNEUROSCI.2405-16.2017
Copyright © 2017 the authors 0270-6474/17/374405-11$15.00/0

Introduction

4406 • J. Neurosci., April 19, 2017 • 37(16):4405– 4415

ticular, converging evidence from lesions, pharmacological studies, and direct measurements of cortical ACh release have
demonstrated the importance of the cholinergic system in endogenous visual attention (Robbins et al., 1989; Muir et al., 1992;
Passetti et al., 2000; Arnold et al., 2002; Bentley et al., 2004; Herrero et al., 2008; Rokem et al., 2010).
Physiologically, ACh alters the spatial properties of receptive
fields (RFs) of visual cortical neurons, thereby changing how
visual space is represented and how visual stimuli are segregated
from one another. In primary visual cortex, application of ACh
reduces the spread of excitatory responses to electrical stimulation in rat visual cortical slice recordings (Kimura et al., 1999)
and decreases the optimal stimulus size for individual V1 neurons
in marmosets (Roberts et al., 2005). In humans, systemic cholinergic enhancement decreases the spread of early visual cortical
excitatory fMRI responses to a visual stimulus (Silver et al., 2008).
These effects of ACh on spatial integration in visual cortex may be
due to an increase in the strength of thalamocortical inputs relative to intracortical lateral connections (Gil et al., 1997; Disney et
al., 2007, 2012; Giocomo and Hasselmo, 2007). Reweighting of
input signals enhances the classical central RF of visual cortical
neurons while decreasing influences from the extraclassical
RF, thereby decreasing the spatial extent of excitatory visual
responses.
Notably, visual spatial attention also affects visual cortical RF
size. These effects depend on eccentricity, and in macaque V1,
attention reduces excitatory RF size for stimuli presented at eccentricities of 2–3 degrees of visual angle (Roberts et al., 2007),
similar to the effects of ACh described above. Furthermore, spatial attention is known to affect the resolution of visual perception (for review, see Anton-Erxleben and Carrasco, 2013), and a
cholinergically mediated reduction in visual RF size is consistent
with an enhanced resolution of visuospatial representations.
However, a link between the physiological effects of ACh on spatial integration of visual cortical responses and on human visual
perception remains to be demonstrated.
In a previous study, we found that cholinergic enhancement
with the cholinesterase inhibitor donepezil decreased behavioral
measures of orientation-specific surround suppression in humans (Kosovicheva et al., 2012). One potential cause of this diminished visual surround suppression by ACh is a decrease in
spatial interactions between the target and its suppressive surround, due to smaller visual excitatory RFs. Here, we directly
tested the effects of ACh on the tuning of visuospatial perception
in humans. We assessed visual tuning by systematically measuring thresholds for detecting a target flanked by distractors at different distances in a double-blind, placebo-controlled, crossover
design.
Furthermore, although most pharmacological studies focus
on a single neurotransmitter, many neuromodulator systems are
simultaneously active and can have related effects on cognition
and perception. In particular, the catecholamines DA and NE
have been implicated in a variety of top-down control and
attention-related processes (Arnsten and Li, 2005; Robbins and
Arnsten, 2009), including spatial attention, working memory,
and arousal (Aston-Jones and Cohen, 2005; Robbins and Arnsten, 2009; Noudoost and Moore, 2011a). Therefore, we examined whether dopaminergic and noradrenergic enhancement in
humans would also influence visuospatial interactions in perception. Specifically, we administered either bromocriptine (a dopamine D2/D1 receptor agonist) or guanfacine (a noradrenergic
␣-2a receptor agonist) and assessed performance on the same
target detection task described above. Combining these studies
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allowed us to determine how enhancement of three distinct neurotransmitter systems affected visual perception and the visuospatial tuning of target–flanker interactions in humans.

Materials and Methods
General. Two separate behavioral pharmacology experiments in different
participant groups with distinct drug manipulations (Experiment 1:
donepezil and placebo; Experiment 2: bromocriptine, guanfacine, and
placebo) are reported here. The same visual target detection task was
completed by participants in both experiments.
Participants. Twenty-eight healthy young adults (14 females; average
age ⫽ 23 years, range ⫽ 19 –34 years) completed Experiment 1, and 23
healthy young adults (11 females; average age ⫽ 23 years, range ⫽ 19 –37
years) completed Experiment 2. An additional participant (Experiment
1) and 8 participants (Experiment 2) did not complete all of the required
sessions.
All participants had normal or corrected-to-normal vision and were
paid for their participation. Exclusion criteria for both experiments included a history of heart arrhythmia, neurological disorders, psychoactive medication, tobacco smoking, and pregnancy. Participants from
Experiment 2 were also required to be right-handed native English
speakers with normal color vision and were excluded if they did not meet
(1) additional MRI screening criteria (had pacemakers, vascular disease,
history of claustrophobia, or history of head trauma) or (2) additional
exclusion criteria for the dopaminergic and noradrenergic medications.
These included hypertension or hypotension (diastolic values ⬍60 or
⬎90 mmHg, systolic values ⬍100 or ⬎160 mmHg), low heart rate (⬍50
beats per minute), low or high body mass index (⬍19 or ⬎30 kg/m 2), or
not meeting neurological assessment score cutoffs (a score of ⬎11 on the
Beck Depression Inventory or ⬎16 errors on the National Adult Reading
Test). Written informed consent was obtained from all participants, and
both experiments were approved by the Committee for the Protection of
Human Subjects at the University of California, Berkeley.
Experimental timeline. Experiments 1 and 2 both used double-blind,
placebo-controlled, crossover designs (Fig. 1).
In Experiment 1 (Fig. 1A), participants completed five sessions on
different days. Session 1 was used to familiarize participants with the task
and with maintaining stable eye position at fixation (see description in
Eye movements section). Participants then completed two pairs of two
sessions: a refresher session (2 and 4) followed the next day by a pharmacological session (3 and 5) in which participants were administered either
a donepezil (5 mg, an acetylcholinesterase inhibitor) or placebo pill. The
refresher sessions served to equalize the amount of recent practice with
the task that participants experienced before taking donepezil or placebo.
Pills were ingested 3 h before the start of the experiment to allow
donepezil to reach peak plasma concentration (Rogers and Friedhoff,
1998). Pharmacological sessions 3 and 5 were separated by at least 2
weeks to ensure that donepezil was fully eliminated from the body (the
half-life of donepezil is ⬃80 h) (Rogers and Friedhoff, 1998). Three or
four task runs were completed in each of the five sessions. The task
procedure was similar on all session days, but only data from the pharmacological sessions were analyzed.
In Experiment 2 (Fig. 1B), participants completed four sessions on
different days. As in Experiment 1, each participant first completed a
training session (Session 1: one practice run of low task difficulty and
three training runs at psychophysical threshold) to become familiar with
the task and with maintaining fixation. The other three sessions consisted
of administration of bromocriptine (1.25 mg, a dopamine D2/D1 receptor agonist, with ⬃100-fold stronger binding affinity for D2 receptors
(Gerlach et al., 2003)), guanfacine (1 mg, an ␣-2a receptor agonist adrenoceptor agonist), or a placebo pill. For each pharmacological session, a
refresher period was conducted immediately after pill ingestion and before the drugs had time to reach high plasma concentrations (see below).
During the refresher period, participants completed two practice runs on
the task. This was followed by extensive behavioral testing and MRI for a
separate project not reported here. Behavioral data for this study were
then collected ⬃4 – 4.5 h after pill ingestion (peak plasma concentration
for bromocriptine occurs ⬃2.5 h after ingestion, with a half-life of ⬃7 h
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tained a small contrast decrement presented
for the entire 250 ms duration. Because the
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stimulus presentation that contained the
1
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1
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variable
time
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contrast decrement was randomly selected
on each trial (for the 50% of trials that had a
Analyzed
data
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Sess
Sess
Sess
contrast decrement), subjects needed to con1
2
3
4
3
Pill administered
tinuously maintain covert attention at the
target location.
Refresher
D/P
Training
Refresher
D/P
At the end of each trial, subjects responded
Session
Session
using one of two buttons to indicate whether or
not there had been a contrast decrement on
B Experiment 2: bromocriptine (B), guanfacine (G), and placebo (G)
that trial. The magnitude of the contrast decre4h
4h
ment was adaptively varied to determine the
4h
1 wk
1 wk
variable
time
//
//
threshold for 75% accuracy on the task and was
Sess 3
Sess1
Sess2
Sess 4
calculated using the Bayesian QUEST staircase
procedure (Watson and Pelli, 1983) (http://
fMRI
fMRI
fMRI
psych.nyu.edu/pelli/software.html#quest) for
Exp
Exp
Exp
each target–flanker distance.
Subjects did not have any time limit to make
Training
Refresher
B/G/P
Refresher
B/G/P
Refresher
B/G/P
their responses, and they were encouraged to
Session
Session
Session
respond as accurately as possible. No contrast
decrements ever occurred in the flankers.
Figure 1. Experimental timeline. A, Experiment 1 contrasted the effects of cholinergic enhancement with donepezil (D) against Auditory feedback was given on every trial,
placebo (P) in a within-subject, double-blind, placebo-controlled experiment with five separate sessions, including two refresher and a visual summary of task performance was
sessions to refamiliarize subjects with the task and to equate recent experience with the task for D and P pharmacological sessions. provided at the end of each 50 trial block to
B, Experiment 2 examined the effects of dopaminergic enhancement (with bromocriptine [B]) and noradrenergic enhancement encourage participants to stay engaged in the
(with guanfacine [G]) in the same visual target detection task. Experiment 2 was also a within-subject, double-blind, placebo- task.
controlled experiment and contained four experimental sessions, with a refresher period at the start of each pharmacological
Procedure. Each session began with a short
session, well before the administered drugs had any significant effects.
practice run (50 trials, ⬃5 min) at a constant
contrast decrement of 50%. This was followed
by 3 or 4 runs of the task. For each run, 50 trials
(Deleu et al., 2002), and peak concentration for guanfacine occurs 1– 4 h
from each target–flanker distance (0.2, 0.8. 1.4, and 2.0 degrees of visual
after ingestion, with a half-life of ⬃17 h (Mosqueda-Garcia, 1990)). Two
angle; edge-to-edge) were pseudo-randomly intermixed (200 trials toor three task runs were completed in each of the pharmacological sestal). There were 10 additional trials at the beginning of each run that were
sions, and 1 week separated each of the three sessions.
discarded to prevent the psychophysical staircase from being overly inIn addition, a number of self-report and physiological measures were
fluenced by the subject’s initial responses. Each run took ⬃15 min, with
collected to assess potential side effects associated with guanfacine and
breaks
and performance summaries provided every 50 trials (⬃5 min). A
bromocriptine. Measurements were made at several time points in each
single experimental session took 1–1.5 h.
session, including at the start of each session before drug intake (Time 1)
The experiment was coded and thresholds were calculated using
and immediately before behavioral testing (Time 3; Time 2 was taken
functions from the Psychophysics Toolbox (http://psychtoolbox.org)
immediately before MRI). Self-report measures included visual analog
(Brainard, 1997; Pelli, 1997; Kleiner et al., 2007). All experiments were
scales of anxiety, mood (happiness, sadness), nausea, dizziness, and faconducted in darkened rooms with a chin rest to stabilize head position.
tigue (fatigue, drowsiness, jitteriness), as well as the State and Trait AnxViewing distance was 40 cm (Experiment 1) or 42 cm (Experiment 2)
iety Inventory. Physiological measures included heart rate and systolic
from the display screen.
and diastolic blood pressure. The differences between predrug and testEye movements. The need to maintain fixation throughout the task was
ing (Time 3 ⫺ Time 1) were compared between the placebo and drug
strongly emphasized to participants in their first training session and
sessions using two-tailed paired t tests, FDR correcting for multiple comagain in the instructions preceding each run. To train participants to
parisons across tests.
maintain fixation, an experimenter monitored eye movements with an
Visual stimuli and task. Participants performed a contrast decrement
infrared camera placed in front of one of the participant’s eyes during the
task on a peripheral (eccentricity of 3 degrees of visual angle) target (25%
first training session. Each participant completed a practice block of
contrast, defined as the SD of the luminance; see Fig. 2, inset) that was
trials, and immediate auditory feedback was provided whenever fixation
flanked by high-contrast distractors (75% contrast; see Fig. 2, inset) while
was broken. By the end of the practice block, participants were able to
maintaining central fixation. Targets and flankers consisted of the same
maintain stable fixation during the task. We have previously used similar
pair of spatially overlapping grayscale face images that were matched for
training procedures and evaluation of fixation stability for similar covert
average luminance and presented on an average luminance gray backattention tasks and have shown that eye movements are infrequent and
ground. These unusual stimuli were selected to allow these data to be
do not differ for donepezil and placebo (⬃0.5% of trials) (Silver et al.,
compared with other experiments on feature-based attention (not re2008; Rokem et al., 2010) or for bromocriptine and placebo (⬃0.3% of
ported here).
trials) (Rokem et al., 2012).
Each trial began with 400 ms of presentation of an arrow-shaped cue at
Analysis. For both experiments, analyses were conducted on the mefixation that indicated the location of the target (either the left or right
dian of the threshold estimates from each run from each participant.
quadrant of the upper visual field) with 100% validity. This was followed
Initial analyses were conducted using a repeated-measures ANOVA with
by a 200 ms cue-stimulus interval and then 2.16 s of a stimulus display
factors of pill type (donepezil and placebo for Experiment 1, bromocripthat flashed at a frequency of 2.78 Hz (six cycles of 250 ms on, 110 ms off).
tine and placebo, or guanfacine and placebo for Experiment 2) and tarThe experimental manipulation was the distance between target
get–flanker distance (0.2, 0.8, 1.4, and 2.0 degrees). Differences between
and flankers, which was pseudorandomly varied on each trial within a
drug effects in Experiment 1 and 2 were compared using a similar mixedrange of 0.2–2.0 degrees of visual angle (stimulus edge-to-edge dismodel ANOVA with an additional between-subjects factor of experitance, or 1.2–3.0 degrees center-to-center distance). The positions of
ment (Experiment 1 or 2). Post hoc t tests were used to compare drug and
the target and flankers were outlined with thin white squares on each
placebo results at specific target–flanker distances. For ease of visualizatrial to decrease spatial uncertainty. On half of the trials, one of the
tion, behavioral performance is displayed in figures in units of sensitivity
five 250 ms stimulus presentations (excluding the first cycle) con-

A Experiment 1 : donepezil (D) and placebo (P)
2h
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cue

time

delay

400 ms

200 ms
response screen + feedback

2.16 s,

d
target

d

flanker
Was there a contrast decrement?
Yes/No

3 deg

flanker

d = 0.2 deg

d = 0.8 deg

d = 1.4 deg

d = 2.0 deg

Figure 2. Task design. Each trial of the task began with a cue pointing to either the left or right top quadrant that indicated the location of the subsequent stimulus display, consisting of a
low-contrast target flanked by high-contrast distractors (shown enlarged in inset, with white borders thickened for visualization). The critical manipulation was the distance between target and
flankers, which varied between 0.2 and 2.0 degrees of visual angle. The participants’ task was to determine whether a slight contrast decrement occurred in the target at some point during the
display period (50% probability). The magnitude of the contrast decrement was adaptively varied from trial to trial to determine the threshold for 75% target detection accuracy.
(1-contrast threshold for 75% accuracy), although statistical analyses
were conducted on raw threshold values.
A second set of analyses was based on previously reported spatial profiles of target-flanker interactions in visual perception (Polat and Sagi,
1993; Müller et al., 2005a) and involved modeling the data with a Difference of Gaussians (DoG) profile, separately for each drug and placebo
session. Unlike the analysis described above, which treats each distance as
an independent condition, this procedure includes an explicit model of
the function relating contrast decrement detection thresholds to targetflanker distance.
We included the following parameters in our model: the amplitude
and SD (width) of a broadly tuned Gaussian that reflects long-range
facilitatory interactions between the target and flankers (Gaussian 1, or
G1; see Fig. 4A) and the amplitude and SD of a more narrowly tuned
Gaussian that reflects shorter-range suppressive target-flanker perceptual interactions (Gaussian 2, or G2; see Fig. 4A).
Data were demeaned before modeling. Model fitting was performed using the fmincon function in MATLAB (R2011b; The
MathWorks), with added constraints that Gaussian 1 had lower am-

plitude and greater width than Gaussian 2 and that all values had to be
positive and ⬍2 (despite the similar bounding values, the units of
measurement for amplitude and SD of the Gaussians were contrast
decrement detection threshold and target-flanker distance in degrees
of visual angle, respectively). This fitting procedure merely translates
the original measurements of contrast threshold at each targetflanker distance into Gaussian parameters, as only four target–flanker
distances were used to fit the four parameters. However, the constraints on parameter values prevent excessive overfitting, and our
main experimental question of interest is the drug effect on each of
the Gaussian parameters, not the parameter values themselves.
Initial values for the fitting algorithm were selected by iterating
through a range of possible initial values for each parameter (0 –1 in steps
of 0.01 and 1–2 in steps of 0.1; at this stage, each parameter was individually fit while other parameters were kept constant at a value of 1) and
then selecting the initial value for each parameter that produced the
lowest error (sum of squared errors) for the fit of each individual experimental session. This sampling scheme and range were used to select
initial parameter values that minimized the frequency of border solu-
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Results
Experiment 1
In Experiment 1, we examined the effects of increasing cholinergic signaling with donepezil on contrast decrement detection of
targets flanked by distractors at different distances (Fig. 2).
Effects of donepezil on target–flanker interactions in
visual perception
Figure 3 shows the effects of target–flanker distance on contrast
decrement detection. Both donepezil and placebo sessions generated a characteristic Difference of Gaussians (DoG) spatial profile of performance: sensitivity was lowest when flankers were
closest to the target, and performance improved at greater distances, eventually plateauing at large distances.
We examined the influence of target–flanker distance on
performance using an ANOVA with within-subject factors of
target–flanker distance (0.2, 0.8, 1.4, and 2.0 degrees) and pill
type (donepezil or placebo). We found a significant main effect of
distance (F(3,81) ⫽ 10.0, p ⬍ 0.001), indicating that target detection was influenced by the distance between the target and
flanker. In addition, there was a significant main effect of drug
(F(1,27) ⫽ 4.64, p ⬍ 0.05), reflecting better overall performance on
donepezil than placebo. Post hoc t tests suggested that the effects
of donepezil were particularly pronounced at intermediate target–flanker distances (distance 0.8: t(27) ⫽ 3.20, p ⬍ 0.005,
p(FDR) ⫽ 0.01; all other distances p(FDR) ⬎ 0.23). However, the
drug by distance interaction term in the ANOVA did not reach
significance (F(3,81) ⫽ 1.38).
Modeling effects of donepezil on facilitatory and suppressive
target–flanker interactions
To quantify the effects of donepezil on the spatial profile of
flanker interference, we fit the data from each individual session
with a DoG model. The model contained four free parameters:
the amplitude (A1) and width (S1) of a positively signed Gaussian
to model facilitatory effects of flankers on target detection, and
the amplitude (A2) and width (S2) of a negative (suppressive)
Gaussian (Fig. 4A; for a more extensive description of the fitting
procedure, see Materials and Methods).
A repeated-measures ANOVA with factors of parameter (A1,
S1, A2, S2) and pill type (donepezil, placebo) showed a significant
interaction between parameter and pill type (F(3,81) ⫽ 4.87, p ⬍
0.005, p(HF) ⫽ 0.01; Figure 4B). Post hoc t tests revealed that the

A

0.74

**

sensitivity (1-threshold)

0.72

0.70
0.68
0.66
0.64

donepezil
placebo

0.62
0.60
0.2

0.8

1.4

2.0

target - flanker distance (deg)

B
sensitivity: donepezil - placebo

tions. This procedure is not biased for any individual condition, as it was
conducted independently for all placebo and drug session data.
The computed model parameters were entered into a repeatedmeasures ANOVA with factors of parameter (amplitude and width of
Gaussian 1, amplitude and width of Gaussian 2) and pill type (donepezil
and placebo for Experiment 1, bromocriptine and placebo or guanfacine
and placebo for Experiment 2). Differences in drug effects between Experiments 1 and 2 were assessed using a mixed-model ANOVA with the
additional between-subjects factor of experiment. In the figures, the drug
effects on each parameter are displayed as contrast indices: (drug ⫺
placebo)/(drug ⫹ placebo). A positive contrast index indicates that the
parameter (width or amplitude) increased in magnitude with the drug,
whereas a negative contrast index indicates that the value of the parameter decreased with the drug.
All ANOVAs were analyzed using the repeated-measures ANOVA
function in SPSS (version 22). If Mauchly’s test indicated a significant
deviation from sphericity, F statistic values were corrected for sphericity
using the Huynh–Feldt procedure; and in these cases, p values are reported as p(HF). All post hoc t tests were FDR-corrected for multiple
comparisons across conditions (i.e., the number of distances tested) using the p.adjust function with method FDR in R (version 3.0.2), and the
resulting p values are reported as p(FDR).
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0.08

0.06

**
0.04

0.02

0
0.2

0.8

1.4

2.0

target - flanker distance (deg)
-0.02

Figure 3. Experiment 1. Effects of donepezil on target–flanker interactions in visual perception. A, The effect of target–flanker distance on sensitivity of contrast decrement detection after
taking a donepezil or a placebo pill. B, The difference between sensitivity for donepezil and
placebo conditions at different target–flanker distances. Compared with placebo, donepezil
increased sensitivity, especially at intermediate (0.8 degree) distances. Error bars indicate
SEM (A) across participants and (B) across participants for the donepezil-placebo difference. **p ⬍ 0.01.

interaction was primarily driven by a significant decrease in the
width of the facilitatory Gaussian (S1; t(27) ⫽ 3.03, p ⬍ 0.01;
p(FDR) ⫽ 0.02), consistent with a sharpened tuning of facilitatory target-flanker interactions in visuospatial perception following cholinergic enhancement. No other parameters differed
significantly across the two experimental sessions (all p ⬎ 0.10).
Experiment 2
Experiment 2 used the same behavioral paradigm and modeling
approach as Experiment 1 to examine how systemically increasing DA and NE levels (through bromocriptine and guanfacine
administration, respectively) influenced target detection and the
spatial profile of target–flanker interactions.
Effects of bromocriptine and guanfacine on
target–flanker interactions
Placebo. Contrast decrement detection thresholds as a function of
target–flanker distance in Experiment 2 are shown in Figure 5A.
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Figure 4. Experiment 1. Modeling effects of donepezil on facilitatory and suppressive target–flanker interactions. A, A DoG curve (G1–G2, right) was fit to the data with four parameters: the
amplitude (A1) and width (S1) of the broad facilitatory Gaussian (G1, gray line) and the amplitude (A2) and width (S2) of the narrower suppressive Gaussian (G2, black dashed line) separately for
placebo and donepezil sessions. B, The cholinergic enhancement effect on each parameter is displayed as a contrast index (drug ⫺ placebo/drug ⫹ placebo). Positive values indicate that the drug
increased amplitude/width, and negative values indicate that the drug decreased amplitude/width for each Gaussian. Compared with placebo, donepezil significantly decreased the spatial extent
of the facilitatory Gaussian (S1). **p ⬍ 0.01.

Performance in the placebo session showed a characteristic DoG
shape across distances, with lowest sensitivity for target detection
when flankers were closest to the target and improving (and then
plateauing) sensitivity for further distances. A between-subjects
ANOVA comparing thresholds from placebo sessions in Experiments 1 and 2 showed no overall difference between the two
(main effect of experiment: F(1,49) ⫽ 0.17; interaction between
distance and experiment: F(3,147) ⫽ 0.53). This indicates that,
although the experimental procedures differed slightly between
the two experiments (see Materials and Methods), our measurements of psychophysical thresholds and spatial interactions were
robust to these differences.
Bromocriptine. A repeated-measures ANOVA comparing thresholds in bromocriptine versus placebo sessions indicated a significant interaction between drug and distance (F(3,66) ⫽ 3.35,
p ⬍ 0.03, p(HF) ⫽ 0.03) but no main effect of drug (F(1,22) ⫽
0.14). Examination of the drug effects at each distance (Fig. 5B)
suggests that the drug ⫻ distance interaction was driven by decreased sensitivity at intermediate distances and a slight increase
in sensitivity at close and very far distances. However, individual
post hoc t tests did not result in significant drug effects at any
target–flanker distance (all p[FDR] ⬎ 0.26).
Guanfacine. A repeated-measures ANOVA comparing guanfacine to placebo resulted in a marginally significant main effect
of drug (F(1,22) ⫽ 3.16, p ⫽ 0.09), with participants exhibiting a
trend toward overall lower sensitivity on guanfacine. No other
main effects or interactions were significant (Fig. 5C).
Self-report and physiological measures
We examined possible effects of bromocriptine and guanfacine
on a number of physiological and self-report measures (Table 1),
using paired t tests to compare the change across time points for
placebo versus drug sessions. There were no significant differences between bromocriptine and placebo or between guanfacine
and placebo for any measure after correcting for multiple
comparisons. Thus, it seems unlikely that systemic physiological effects of guanfacine or bromocriptine (e.g., drowsiness,
dizziness) strongly affected either performance in our visuospatial task or perceptual tuning.

Comparison with Experiment 1
We directly compared the results of Experiments 1 and 2 by
adding a between-subject factor of Experiment to each ANOVA.
For bromocriptine compared with donepezil, this analysis identified a significant interaction of pill type, distance, and experiment (F(3,147) ⫽ 4.68, p ⬍ 0.005). This demonstrates that
donepezil and bromocriptine have significantly different effects
on the spatial profile of target–flanker interactions. No other interactions were significant.
For the comparison of guanfacine to donepezil, there was a
pill type ⫻ experiment interaction (F(1,49) ⫽ 7.02, p ⬍ 0.02,
p[HF] ⬍ 0.02), with a weak trend for the three-way pill type ⫻
distance ⫻ experiment interaction (F(3,147) ⫽ 2.05, p ⫽ 0.11). No
other interactions were significant. Thus, donepezil and guanfacine have significantly different effects on target detection that
weakly interact with the distance between targets and flankers.
Modeling effects of bromocriptine and guanfacine on
facilitatory and suppressive target–flanker interactions
As in Experiment 1, the specific effects of bromocriptine or guanfacine on the spatial profile of target–flanker interactions were
examined with a DoG model (Fig. 6). An ANOVA comparing
bromocriptine and placebo for the DoG parameters (A1, S1, A2,
S2) showed no significant effects of pill type or interactions (all
p ⬎ 0.44). Similarly, there were no significant effects of pill type
or interactions in an ANOVA comparing guanfacine and placebo
(all p ⬎ 0.58). These findings indicate that, for both DA and
NE, pharmacological enhancement of signaling did not alter
either facilitatory or suppressive interactions between targets
and flankers.
Comparison with Experiment 1
We compared model parameter values directly across experiments with an ANOVA that had an additional between-subject
factor of experiment (Experiment 1 or 2). For both bromocriptine versus donepezil (F(3,147) ⫽ 4.54, p ⬍ 0.01) and guanfacine
versus donepezil (F(3,147) ⫽ 3.11, p ⫽ 0.028), there was a significant three-way interaction of pill type, parameter, and experiment. These interactions indicate that cholinergic enhancement
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A

had a significantly different influence on the spatial profile of
target–flanker interactions compared with either DA or NE enhancement, as described by the model parameters. No other interactions of drug or experiment were significant.
Placebo. Finally, analysis of parameter estimates revealed no
significant interactions between the placebo data from Experiment 1 and the placebo data from Experiment 2 (F(3,147) ⫽ 0.75).
This provides further evidence that placebo data, and therefore
the experimental procedures, were comparable for Experiments
1 and 2.
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We have found that cholinergic enhancement with donepezil
improved performance in a task requiring sustained attention to
a target with flanking distractors, particularly at intermediate target–flanker distances. Modeling showed that donepezil decreased
the width of facilitatory target–flanker interactions, corresponding to sharpened spatial tuning. In contrast, neither bromocriptine nor guanfacine systematically improved performance or
affected the spatial tuning of perception.

sensitivity: bromocriptine - placebo

0.06
0.04
0.02
0

0.2

0.8

1.4

2.0

-0.02
-0.04
-0.06
-0.08

target - flanker distance (deg)

-0.10

C

0.06

sensitivity: guanfacine - placebo

0.04
0.02
0

0.2

0.8

1.4

2.0

-0.02
-0.04
-0.06
-0.08
-0.10

target - flanker distance (deg)

Figure 5. Experiment 2. Effects of bromocriptine and guanfacine on target–flanker interactions. A, The effect of target–flanker distance on sensitivity of contrast decrement
detection after taking placebo (white circles), bromocriptine (light gray), or guanfacine
(dark gray). Data points have been slightly offset from one another to facilitate visualization,
but target–flanker distances were the same in all drug conditions. B, Paired differences between bromocriptine and placebo sessions. Bromocriptine weakly modulated target–flanker

Relationship between cholinergic effects on visuospatial
tuning of behavior and neuronal RFs
What is the relationship between the perceptual effects of ACh that
we observed and its physiological effects in early visual cortex? Neuronal RFs in V1 have three components: (1) central excitation driven
by thalamocortical inputs, (2) a “near” surround that is driven primarily by local horizontal connections and can be excitatory or inhibitory, depending on stimulus properties such as contrast and
orientation, and (3) an extensive “far” inhibitory surround driven
mainly by feedback connections (Angelucci and Bressloff, 2006;
Nurminen and Angelucci, 2014). Thus, for single neuron RFs, the
spatial tuning of inhibition is broader than that of excitation.
ACh has differential actions on these inputs to visual cortical
neurons, strengthening thalamocortical connections relative to
lateral connections (Gil et al., 1997; Disney et al., 2007, 2012;
Giocomo and Hasselmo, 2007). Given that RFs of excitatory thalamic inputs to cortex are smaller than those from V1 intracortical connections, a cholinergically mediated enhancement of
feedforward processing is consistent with a reduction in excitatory RF size in visual cortex. Indeed, increasing cholinergic signaling reduces excitatory RF size of marmoset V1 neurons
(Roberts et al., 2005) and decreases the spatial extent of excitatory
visual responses in human visual cortex, as measured with fMRI
(Silver et al., 2008). Our finding that cholinergic enhancement
reduces the extent of facilitatory spatial interactions in perception is therefore conceptually consistent with the fact that ACh
decreases excitatory RF size in visual cortex.
However, unlike individual visual cortical neurons, the spatial
profile of target-flanker interactions in our perceptual task is
characterized by poorest performance at short target-flanker distances and best performance at intermediate distances, consistent
with broadly tuned facilitation and narrowly tuned suppression
(Fig. 4A). This pattern has also been observed for collinear oriented Gabor patches (Polat and Sagi, 1993), circular targets
flanked by circular stimuli (Yu and Levi, 1997), and letter stimuli
(Müller et al., 2005a).
4
interactions at different distances, tending to decrease sensitivity at intermediate distances.
C, Paired differences between guanfacine and placebo sessions. Guanfacine had no significant
effect on target detection, although participants showed a trend toward impaired overall
performance.
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Table 1. Physiological and self-report measuresa
Placebo (P)

Heart rate
Blood pressure, systolic
Blood pressure, diastolic
VAS, anxious
VAS, happy
VAS, sad
VAS, nauseous
VAS, drowsy
VAS, jittery
VAS, fatigued
VAS, dizzy
State anxiety

Bromocriptine (B)

t test p value,
Time 3 ⫺ Time 1

Guanfacine (G)

Time 1

Time 3

Time 1

Time 3

Time 1

Time 3

B-P

G-P

66.3 (10.7)
119.0 (11.6)
68.9 (7.2)
1.4 (1.7)
6.3 (1.4)
0.9 (1.0)
1.1 (1.3)
2.1 (1.8)
0.7 (0.8)
2.5 (2.0)
0.7 (0.8)
28.9 (7.7)

66.0 (11.5)
122.1 (11.2)
71.3 (10.2)
1.3 (1.7)
6.2 (1.7)
0.7 (1.0)
0.7 (0.6)
2.0 (1.9)
1.0 (1.3)
2.5 (2.0)
1.1 (1.4)
28.3 (5.8)

69.7 (13.0)
119.0 (11.6)
66.7 (8.1)
1.4 (1.4)
6.2 (1.5)
1.1 (1.2)
0.9 (1.0)
1.9 (1.8)
1.1 (1.4)
1.9 (1.5)
0.6 (0.8)
29.9 (6.0)

69.2 (11.5)
117.3 (10.8)
68.1 (9.8)
1.1 (1.2)
6.1 (1.8)
0.9 (1.1)
1.0 (1.1)
2.3 (2.1)
1.1 (1.2)
2.8 (2.3)
1.3 (1.6)
29.0 (7.1)

70.2 (13.6)
118.7 (11.5)
68.6 (9.6)
1.5 (1.4)
6.3 (1.3)
1.0 (1.3)
0.9 (1.1)
2.3 (2.0)
1.0 (1.2)
2.3 (1.8)
0.7 (1.0)
28.4 (5.3)

68.4 (9.6)
118.2 (11.1)
68.8 (9.0)
0.8 (1.1)
6.4 (1.4)
0.8 (1.2)
0.9 (1.2)
2.5 (2.4)
0.8 (1.3)
2.6 (2.5)
0.8 (1.4)
27.8 (5.4)

n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.

n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.

a

Comparison of the change in physiological (heart rate and blood pressure) or self-report (anxiety, mood, nausea, dizziness, and fatigue) measures collected in Experiment 2, after ingesting drug (guanfacine or bromocriptine) versus placebo.
No measure showed a significant drug effect. Values represent mean (SD). Time 1 is before drug intake; Time 3 is after drug intake, preceding behavioral testing. VAS, Visual analog scale. State anxiety was measured using the State and Trait
Anxiety Inventory (STAI). n.s., Not significant (p ⬎ 0.05, paired two-tailed t test, FDR-corrected for multiple comparisons).

drug contrast index
(drug - placebo)/(drug + placebo)

This apparent discrepancy between spaA
B
Dopaminergic
Noradrenergic
tial profiles in perception and neuronal RFs
30
30
can be explained by the observation that
20
20
contrast discrimination performance is related to the slope of the neural contrast re10
10
sponse function (CRF), rather than the
absolute magnitude of neural responses that
0
0
A1
S1
A2
S2
A1
S1
A2
S2
are typically used to characterize neuronal
RFs (Geisler and Albrecht, 1997). In our
-10
-10
task, a higher CRF slope would be associated
-20
-20
with better behavioral contrast discrimination of the contrast decrement target, relaDoG parameter
DoG parameter
-30
-30
tive to preceding/subsequent contrasts.
Given that neural CRFs saturate at
Figure 6. Experiment 2. Modeling effects of bromocriptine and guanfacine on facilitatory and suppressive target–flanker
higher stimulus contrasts, a lower firing interactions. Drug effects on the Gaussian parameter values for bromocriptine and placebo (A) and guanfacine and placebo (B)
rate can therefore improve contrast dis- sessions from Experiment 2. Unlike the effects of cholinergic enhancement (Fig. 4B), no significant differences were seen for any
crimination. Accordingly, the addition of parameters for either bromocriptine or guanfacine.
nearby flanking stimuli (assumed to be
within the central excitatory portion of
detection across the neuronal population for intermediate target/
the RFs of neurons mediating task performance) impairs behavflanker distances.
ioral contrast discrimination (Yu and Levi, 1997), presumably by
shifting responses to a more saturated portion of the CRF. On the
Could cholinergic modulation of visual spatial perceptual
other hand, flankers placed at a distance corresponding to the
tuning arise from top-down attention effects?
presumed inhibitory RF surround reduce neuronal response amAnother interpretation of our findings is that cholinergic enplitude but improve behavioral contrast discrimination (Yu and
hancement influenced the spatial profile of target–flanker interacLevi, 1997), presumably by shifting neurons to the part of the
tions by augmenting the effects of top-down spatial attention
CRF that has higher slope.
(Newman et al., 2012). Attention modulates center/surround interactions in neurons in macaque V4 (Sundberg et al., 2009) and
Relatedly, increasing the size of a grating increases fMRI reMT (Anton-Erxleben et al., 2009), and top-down spatial attensponse amplitudes in human visual cortex while impairing contion itself has been proposed to have a center/surround spatial
trast discrimination of a small target overlaid on the grating when
profile (Müller and Kleinschmidt, 2004; Müller et al., 2005a; Silthe grating is relatively small (and presumed to correspond to the
ver et al., 2007; Hopf et al., 2010).
central excitatory part of the RFs of neurons mediating task perMoreover, ACh is related to the effects of top-down attention.
formance), but the opposite pattern of results is obtained when
In rodents, levels of ACh release in prefrontal cortex track attenthe grating is larger (Nurminen et al., 2009). Thus, while single
neurons have narrow excitatory RFs and broad inhibitory RFs,
tional effort, including increased demands in attention tasks
tuning in perceptual contrast discrimination follows the opposite
caused by adding distractors (for review, see Sarter et al., 2005).
In humans, donepezil increases the beneficial effects of top-down
pattern, with narrow suppressive and broad facilitatory effects,
spatial attention on visual perception (Rokem et al., 2010). In
consistent with our modeling results (Fig. 4A).
In this framework, a reduction in the spatial extent of facilitatory
addition, blockade of muscarinic ACh receptors eliminates atteninteractions in contrast decrement detection following donepezil adtional modulation of visual responses in macaque V1 (Herrero et
al., 2008).
ministration is consistent with smaller excitatory neuronal RF size.
Improved visuospatial perceptual tuning through cholinergic
Specifically, ACh shrinks excitatory RFs, thereby increasing the likemodulation of attention would also account for our previous
lihood of flankers falling in the inhibitory surround of a given neufinding that cholinergic enhancement with donepezil decreased a
ron’s RF. This, in turn, results in improved contrast decrement
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behavioral measure of orientation-tuned surround suppression
(Kosovicheva et al., 2012). Specifically, ACh may have increased
attentional suppression of distractors (the flankers in the present
study; the suppressive surround in Kosovicheva et al. (2012),
thereby improving performance and perceptual spatial tuning. In
this case, the facilitatory Gaussian in our model could be interpreted as enhanced performance due to suppression of distractors by top-down spatial attention.
Finally, we note that cholinergic effects on top-down attention
and on spatial properties of visual RFs are not incompatible with
one another. A gating mechanism for top-down attention in
visual cortex could act in concert with ACh release to facilitate
feedforward processing of stimuli at attended locations, increasing response amplitudes and decreasing excitatory RF size,
thereby improving the spatial resolution of perception. In this
context, it is notable that top-down spatial attention can modulate both excitatory RF size of V1 neurons (Roberts et al., 2007)
and the spatial resolution of visual perception (Yeshurun et al.,
2008) in an eccentricity-dependent manner. An exciting research
direction for the future is to characterize the eccentricity dependence of cholinergic effects on physiological and perceptual spatial resolution and how these effects interact with attention and
task demands.
Models of dopaminergic and noradrenergic action in spatial
tuning and visual attention
Both the DA and NE systems have been implicated in attentional
processes (for reviews, see Arnsten and Li, 2005; Aston-Jones and
Cohen, 2005; Robbins and Arnsten, 2009; Noudoost and Moore,
2011b). However, in our study, the effects of cholinergic enhancement were fundamentally different from those of dopaminergic and noradrenergic enhancement, revealing a selective
influence of ACh on visuospatial perception.
We enhanced dopaminergic activity through systemic administration of bromocriptine, a D2/D1 receptor agonist. We found
no effect on overall task performance. In addition, although there
was an interaction of drug and target–flanker distance for bromocriptine, this was not reflected in a systematic change in the
DoG profile. These findings appear to contrast with previous
neural studies in which both DA receptor agonists (Vijayraghavan et al., 2007) and antagonists (Williams and Goldman-Rakic,
1995) sharpened the tuning of spatially selective neurons in macaque prefrontal cortex during the delay period of a working
memory task. In addition, Noudoost and Moore (2011a) found
that DA receptor antagonists applied to the macaque frontal eye
fields, a source of top-down attention signals to visual cortex
(Moore and Armstrong, 2003), enhanced response amplitude
and sharpened orientation tuning for neurons in cortical area V4.
However, these physiological effects were specific to D1 rather
than D2 receptor modulations (Williams and Goldman-Rakic,
1995; Vijayraghavan et al., 2007; Noudoost and Moore, 2011a).
Indeed, altering D2 receptor signaling either caused generalized
suppression of responses (Williams and Goldman-Rakic, 1995)
or influenced saccadic target selection but not visual tuning in V4
(Noudoost and Moore, 2011a). D1 and D2 receptors have
different distributions in the brain (e.g., higher densities of D1
receptors in prefrontal cortex) and have been linked to distinct
and sometimes even antagonistic cognitive effects (Cools and
D’Esposito, 2011).
Bromocriptine has some binding affinity for both D1 and D2
receptors, although it binds ⬃100-fold more strongly to D2 receptors (Gerlach et al., 2003). Therefore, bromocriptine likely
influenced both D1 and D2 receptor signaling in our study, but
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D2 receptor effects may have been more pronounced. Given the
studies cited above, a dominant effect of bromocriptine on D2
receptors would be consistent with the lack of perceptual tuning
effects that we observed following bromocriptine administration.
While previous studies have found that bromocriptine (via a
combination of D2/D1 receptor activation) can influence a variety of top-down functions, such as cognitive control and working
memory in humans (Kimberg et al., 2001; Gibbs and D’Esposito,
2005; Cools et al., 2007, 2009; Wallace et al., 2011; Stelzel et al.,
2013; for review, see Cools and D’Esposito, 2011), our findings
suggest that it does not substantially affect visuospatial perceptual
tuning. More research is needed to establish how targeted
modulation of D1 versus D2 receptors may influence visual
perception in humans.
Noradrenergic activity is also thought to modulate attention
via a prefrontal mechanism (Arnsten and Li, 2005; Aston-Jones
and Cohen, 2005). We manipulated NE function with guanfacine, an ␣-2a receptor agonist, which are found primarily on
postsynaptic pyramidal neurons, suggesting that this is the primary site of their action (Arnsten and Li, 2005). These receptors
have been associated with the beneficial effects of NE in prefrontal cortex, improving working memory performance in mice,
rats, and monkeys, whereas blocking receptors creates symptoms
of attention deficit hyperactivity disorder (ADHD) (for review,
see Arnsten and Li, 2005). Systemic administration of guanfacine
to healthy humans (Jäkälä et al., 1999), individuals with traumatic brain injury (McAllister et al., 2011), or individuals with
ADHD (Hunt et al., 1995; Scahill et al., 2001) can lead to improved performance on a variety of cognitively demanding tasks
(but see also lack of effects in Müller et al., 2005b; McAllister et al.,
2011).
Despite these beneficial effects of NE on cognitive performance, we found that noradrenergic enhancement with guanfacine trended toward impairing target detection performance
across all target–flanker distances. One possibility is that guanfacine does not strongly modulate lower-level visual attention tasks
or target–flanker interactions in the absence of higher-level (e.g.,
working memory, cognitive control) cognitive demands or noradrenergic system disruption (e.g., in participants with ADHD,
brain injury, or aging).
Finally, although all of the drugs used in our experiments have
previously been shown to modulate human cognition, they have
different mechanisms of action. We enhanced cholinergic processing by inhibiting acetylcholinesterase, the enzyme that breaks
down ACh, thereby prolonging the actions of endogenously released ACh in a manner that is not selective for particular receptor subtypes. In contrast, our manipulations of the dopaminergic
and noradrenergic systems were through agonists that tonically
activate specific receptor subtypes. Therefore, the molecular
mechanisms of action were not equivalent across the three pharmacological interventions used in this study, and the three drugs
may have also varied in their influence on release of endogenous
neurotransmitters through autoreceptor activation. These issues
emphasize that the interpretation of systemic pharmacological
manipulations in humans can be complex and suggest that complementing this research with more invasive manipulations in
animal models will be very informative.
Conclusion
In conclusion, here we demonstrate that cholinergic enhancement with donepezil improves visuospatial perception in a manner consistent with sharpened perceptual tuning. These effects
were selective: enhancement of the noradrenergic or dopaminer-

4414 • J. Neurosci., April 19, 2017 • 37(16):4405– 4415

gic systems did not improve visuospatial perception or alter its
tuning. Our findings link the physiological and perceptual effects
of ACh on visuospatial integration. Furthermore, they suggest a
potential cholinergic mechanism for the effects of selective attention in visual cortex.
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